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Abstract
Predictive modeling based on genomic data has gained popularity in biomedi-
cal research and clinical practice by allowing researchers and clinicians to identify
biomarkers and tailor treatment decisions more efficiently. Analysis incorporat-
ing pathway information can boost discovery power and better connect new find-
ings with biological mechanisms. In this article, we propose a general framework,
Pathway-based Kernel Boosting (PKB), which incorporates clinical information and
prior knowledge about pathways for prediction of binary, continuous and survival
outcomes. We introduce appropriate loss functions and optimization procedures
for different outcome types. Our prediction algorithm incorporates pathway knowl-
edge by constructing kernel function spaces from the pathways and use them as
base learners in the boosting procedure. Through extensive simulations and case
studies in drug response and cancer survival datasets, we demonstrate that PKB
can substantially outperform other competing methods, better identify biological
pathways related to drug response and patient survival, and provide novel insights
into cancer pathogenesis and treatment response.
Keywords: pathway; boosting; kernel methods; prediction; genomic data
1 Introduction
High-throughput genomic technologies have proved powerful to advance our understand-
ing of the associations between genes and clinical phenotypes of interest.1 The analyses
of these data have provided valuable insights into cancer mechanisms, pathogenesis and
treatment response.2–4 Because signals of a single gene in clinical phenotypes can be weak
and one gene is often involved in multiple biological processes, gene level results are often
unstable and lack interpretability. Pathway-based analysis offers a more informative and
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robust alternative, since it can aggregate signals from individual genes and its results are
more easily interpretable. As a result, pathway-based methods have gained popularity
and led to successful identifications of many disease and/or treatment relevant pathways
with better power and interpretability in recent years.5,6 It has been found that the onset
and progression of a disease is usually affected by many pathways.7–9 However, most of
the exsiting pathway-based methods estimate the effects on phenotypes or evaluate the
statistical significance for each pathway separately, and thus cannot quantify the effect
of a given pathway in addition to other pathways.5,10,11 Therefore, there is a need for
methods that integrate all the pathways in the model at the same time.
Nonparametric Pathway-based Regression (NPR)12 and Group Additive Regression
(GAR)13 are two of the early attempts to jointly model all pathways. They extended the
Gradient Descent Boosting (GDB)14 framework to minimize the empirical loss function
of different types of dependent variables. GDB is a functional gradient descent algorithm
that minimizes the empirical loss function. At each iteration of the algorithm, an incre-
ment function in the space of base learners is selected to achieve the steepest descent
to the loss function, and added to the additive model. NPR uses regression trees while
GAR uses linear models to construct base learners from different pathways. However, due
to the linearity assumption of GAR, it lacks the ability to capture complex interactions
among genes in the same pathway. Using regression trees as base learners, NPR can
model interactions but there is no regularization in the gradient descent step, which can
lead to selection bias for large pathways.
In a previous work,21 we proposed a pathway-based kernel boosting (PKB) algorithm
that can utilize patients’ gene expression data and prior pathway knowledge from existing
databases to perform binary classification. We used the second order approximation of the
loss function instead of the first order approximation which is used in the classic gradient
descent boosting method, to allow for deeper descent at each step. A kernel function
space was constructed from each pathway, and the union of the kernel function spaces
was used as the base learner space. From theories of the Reproducing Kernel Hilbert
Space (RKHS)22, this base learner space is flexible enough to capture complex gene-gene
interactions. In order to prevent overfitting, we introduced two types of regularizations
(L1 and L2) for selection of base learners at each iteration. However, two drawbacks of the
model limit the usefulness of PKB in cancer data analysis. First, typical cancer genomic
study datasets provide both patients’ genomic features as well as clinical features, but only
genomic features are considered as predictors in this method, which cannot capitalize on
the rich clinical information that is potentially predictive. Second, PKB can only model
binary outcome variables, which excludes the analysis for other types of interesting clinical
outcomes, such as drug response, disease free survival, and overall survival.
In this article, we propose an extended PKB framework. It enables the inclusion of
clinical features as predictors by adding a linear model component to the base learner
spaces. It also unifies classification, regression, and survival analysis under the same
boosting procedure, which handles different types of outcome variables by specifying
different loss functions. We provide details of the proposed framework in Section 2.
Through extensive simulations in Section 3, we demonstrate that PKB substantially
outperforms competing methods including LASSO,23 Ridge Regression,24 and Elastic-
Net25 in predicting continuous outcomes, and Glmnet,26 RandomSurvivalForest,27 and
CoxBoost28 in predicting survival outcomes. For applications, we evaluate the perfor-
mances of our proposed method on two databases: the Cancer Cell Line Encyclopedia
(CCLE)29 for cell line drug response prediction, and The Cancer Genome Atlas (TCGA)30
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for patient survival prediction in Section 4.
2 Materials and methods
Suppose our observed data are collected from N subjects. For subject i, we use a p
dimensional vector xi = (xi1, xi2, . . . , xip) to denote his/her normalized gene expression
profile. Similarly, the gene expression levels of a given pathway m with pm genes can
be represented by x
(m)
i = (x
(m)
i1 , x
(m)
i2 , . . . , x
(m)
ipm
), which is a sub-vector of xi. We use
zi = (zi1, zi2, . . . , ziq) to represent available clinical features for this subject, such as sex,
age, and cancer type.
For classification, each subject has an observed class label yi ∈ {1,−1}. The proba-
bility of being class 1 is modeled as
p(y = 1|x, z) = exp[F (x, z)]
1 + exp[F (x, z)]
,
where F (x, z) is the log odds function of the classification model. Maximizing the likeli-
hood is equivalent to minimizing the following log loss function:21
l(y, F (x, z)) = log(1 + exp[−yF (x, z)]).
In the regression model, we observe continuous outcome y for each subject. The loss
function for regression is the commonly used squared error:
l(y, F (x, z)) = (y − F (x, z))2
In the survival model, outcome for each subject is a bivariate tuple y = (t, δ), where
t is the survival time or censoring time, and δ is an indicator of the endpoint event, such
as disease relapse or death in most cancer studies. When δ = 1, t is the actual survival
time and when δ = 0, t is the censoring time. We build the survival model following the
Cox regression’s assumption on the hazard function, but replacing the linear component
with a nonlinear risk score function F (x, z):31
h(t, F (x, z)) = h0(t) exp[F (x, z)] (1)
where h0(t) is an unknown baseline hazard function. Using the partial likelihood function
allows us to circumvent the inference of h0(x) and directly estimate F (x, z). We use the
negative log partial likelihood31 as the loss function in the survival model:
l(y, F (x, z)) = −δ
{
F (x, z)− log
(
N∑
j=1
1{tj≥t} exp[F (x, z)]
)}
.
The goal of PKB is to estimate F (x, z) non-parametrically through a boosting pro-
cedure. F (x, z) has different interpretations in different loss functions. We will refer to
it as the score function for the rest of the article.
2.1 Base learner space
Results from theories of RKHS22 have shown that kernel functions can capture complex
interactions among input features. It was used in Zeng et al.21 to construct base learner
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spaces for classification purpose. We extend this formulation by incorporating clinical
features as a linear component in the base learner space. For pathway m, the base
learner space takes the following form:
Gm = {f(x, z) =
N∑
i=1
Km(x
(m)
i ,x
(m))βi +
q∑
j=1
zjγj : β ∈ RN , γ ∈ Rq}, (2)
where Km(·, ·) is a kernel function that defines the similarity between two subjects using
only genes in the mth pathway. Each element in the space is composed of two parts: a
nonlinear component to model gene expression effect and a linear component to model
clinical features’ effects. The overall base learner space G is the union of individual learner
spaces from each pathway: G = ⋃Mm=1 Gm.
Assume that there are M pathways considered in our model. Since genes within
the same pathway likely have stronger interactions than genes in different pathways, we
assume additive effects across pathways and focus on capturing gene interactions within
pathways:
F (x, z) =
M∑
m=1
Hm(x
(m), z),
where each Hm is a function that only depends on the expression level of genes in the
mth pathway and the clinical features. Hm belongs to the RKHS of the mth pathway
Gm. Due to the additive nature of this model, it only captures gene interactions within
each pathway but not across pathways.
Given a specific response type and the corresponding loss function, the empirical loss
is defined as the mean loss evaluated at each sample point:
L(y,F) =
1
N
N∑
i=1
l(yi, F (xi, zi)),
where F = (F (x1, z1), F (x2, z2), . . . , F (xN , zN)). For the rest of this article, we will also
use the boldface font of a function to represent the vector of the function evaluated at
each observed sample point.
2.2 Identification of the optimal increment function
Boosting is an iterative functional descent procedure to minimize the empirical loss func-
tion. Assume that after iteration t, the estimated target function is Ft(x, z). In the next
iteration, we want to identify an “optimal” increment function f ∈ G, which shrinks the
current empirical loss as much as possible, and then add it to Ft(x, z) to yield Ft+1(x, z).
We approximate the loss function L(y,Ft+1) by its second order Taylor expansion
around Ft:
L(y,Ft + ft) ≈ L(y,Ft) + (∇FtL)T ft +
1
2
ft
THFtft
=
1
2
(ft + H
−1
Ft
∇FtL)THFt(ft + H−1Ft∇FtL) + const,
where ft is the increment direction at iteration t. ∇FtL and HFt are the gradient and Hes-
sian matrix of L(y,Ft) with respect to Ft, respectively, and const includes all the terms
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that do not involve ft. Note that this approximation is accurate in the case of regression,
since the regression loss is quadratic itself. Closed form expressions of ∇FtL and HFt for
different problems are given in Appendix A of the Supplementary Materials. Direct
minimization for this loss approximation in G, however, may lead to overfitting, due to
the high flexibility of the base learner space. It is necessary to apply penalties in the
selection of the increment function ft. Here we propose the following regularized loss as
the working loss function in PKB:
LR(ft) =
1
2
(ft + H
−1
Ft
∇FtL)THFt(ft + H−1Ft∇FtL) + λΩ(ft),
where Ω(ft) is the penalty term. Since ft takes the functional form as presented in
Equation (2), it is natural to consider the L1 and L2 norms of βt penalty: Ω(ft) =
‖βt‖1 or ‖βt‖22. Such a penalized boosting step has been employed in several methods.32
Intuitively, the regularized loss function would prefer simple solutions that also fit the
observed data well, which usually leads to better generalization capability to unseen data.
Optimizing LR(ft) in Gm is equivalent to solving
min
βt,γt
1
2
(Kmβt + Zγt + H
−1
Ft
∇FtL)THFt(Kmβt + Zγt + H−1Ft∇FtL) + λΩ(ft), (3)
where Km is the N × N kernel matrix calculated using gene expressions in the mth
pathway, and Z is the N × q clinical feature matrix. It can be proved that, by applying
the following transformation:
η˜t =
1√
2
H
1
2
Ft
(IN − Z(ZTHFtZ)−1ZTHFt)H−1Ft∇FtL
K˜m =
1√
2
H
1
2
Ft
(IN − Z(ZTHFtZ)−1ZTHFt)Km,
solving βt in Equation (3) is reduced to:
min
βt
‖η˜t + K˜mβt‖22 + λΩ(ft). (4)
Proof is provided in Appendix B in the Supplementary Materials. Equation (4)
becomes the LASSO problem when we use the L1 penalty, and the Ridge Regression when
we use L2 penalty. Both can be efficiently solved with existing solvers. After solving βt,
we subsequently obtain the solution of γt as:
γt = −(ZTHFtZ)−1ZTHFt(Kmβt + H−1Ft∇FtL).
With βt and γt solved, we obtain the best increment direction ft.
2.3 The PKB algorithm
In this section we propose the PKB algorithm that solves classification, regression, and
survival analysis in a unified framework in Algorithm 1. Ft(x, z) is the estimated score
function at iteration t, and FT (x, z) is the final score function estimation.
The learning rate parameter ν takes value in (0, 1), usually smaller than 0.1. Our
experience shows that the combination of the line search technique and the learning rate
parameter makes the model fitting procedure more stable, and less prone to overfitting.
5
Algorithm 1: Unified PKB framework
Input: normalized gene expreesion profile with pathway information x; clinical
features z; outcome y; loss function l; learning rate parameter ν ∈ (0, 1);
iterations number T .
Initialization: Initialize F0(x, z) as a constant that minimizes the empirical loss
F0(x, z) = arg min
c
1
N
N∑
i=1
l(yi, c).
In the case of survival model, we set F0(x, z) = 0, because the partial likelihood
of Cox model is not affected by constants.
while T > 0 do
1. Identify the optimal increment function ft.
Calculate the gradient ∇FtL and Hessian matrix HFt . For each pathway m, solve
the optimal fˆm ∈ Gm and corresponding β, γ following the steps in Section 2.2.
The optimal increment function ft is the fˆm which yields the smallest LR(ft).
2. Line search and update Ft
Decide the step length. First perform a line search
dt = arg min
d∈R+
L(y,Ft + dft).
Then apply a shrinkage on the step size using the learning rate parameter ν, and
update the estimate of the score function:
Ft+1(x, z) = Ft(x, z) + νdtft(x, z).
T ← T − 1
end
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The choice of T is critical to prediction accuracy on test data. Choosing a T-value
that is too small or too large can lead to underfitting and overfitting, respectively. We
employ a cross-validation procedure to determine the number of iterations for T . We
split the dataset into three folds, and simultaneously initiate three runs of Algorithm
1, each using two folds as training data and the other fold as testing data. After each
iteration, a cross-validated loss is calculated by averaging the three losses. We keep track
of the minimum cross-validated loss. If the minimum loss value does not change in 50
iterations, we end the cross-validation process, and use the iteration with the minimum
loss as the number of iterations T.
Both the L1 and L2 boosting algorithms require the specification of the penalty pa-
rameter λ, which controls step length (the norm of fitted β) in each iteration for L1 and
L2 and additionally controls solution sparsity in L1 case. Poor choices of λ can result in
big leaps or slow descent speed. To address this issue, we also incorporate an optional
automated procedure to choose the value of λ in PKB. Computational details of the
procedure are provided in Section 2 of the Supplementary Materials of Zeng et al.21
After fitting the PKB model, the final score function estimate takes the form
FT (x, z) =
M∑
m=1
N∑
i=1
Km(x
(m)
i ,x
(m))β
(m)
i + z
Tγ,
where β(m) is the coefficient vector for pathway m. The values of β(m) can be used
to evaluate the significance of pathways in the score function. We propose to use the
L2 norm, wm = ‖β(m)‖2, as weights for pathways. Note that wm is non-zero only if
the pathway is selected at least once during model fitting. From our experience, in
applications with a large number of input pathways, many pathways will end up with
zero weights.
3 Simulation Study
In this section, we apply PKB to a variety of simulation datasets, and demonstrate that it
can yield better prediction accuracy compared to competing methods, as well as correctly
identify informative pathways for regression and survival models.
We design the following three models for the underlying true score functions F (x, z):
Model 1,
F (x, z) = 3z1 − 4z2 + 3z3 + 2x(1)1 + 3x(1)2 + 3 exp(0.5x(2)1 + 0.5x(2)2 ) + 4x(3)1 x(3)2 ;
Model 2,
F (x, z) = z1 − 3z2 + 3z3 − z4 + 6 sin(0.5x(1)1 + 0.5x(1)2 ) + 2 log(|x(2)1
3 − x(2)2
3|) + 2(x(3)1
2 − x(3)2
2
);
Model 3,
F (x, z) = z1 + z3 + 2
∑8
m=1 ‖x(m)‖2.
In the above equations, x
(m)
i represents the expression level for the ith gene in pathway
m. The three models involve a wide variety of functional forms of pathway effects,
including linear, polynomial, exponential, logarithm, and sine effects. We assume the
effects from clinical variables are linear.
Under each model, we simulate two datasets, with 20 and 50 pathways, respectively.
Note that in Models 1 and 2, only the first three pathways are informative, and in
Model 3, the first eight pathways are informative. The predictive signals in the datasets
with 50 pathways are sparser than the 20-pathway datasets. For each pathway, we simu-
late expression levels for five genes using Gaussian distribution. In each dataset, we also
7
generate five clinical features: two binary features generated from Bernoulli distribution,
and three continuous features generated from Normal distribution. The number of pre-
dictive clinical variables is three, four, and two for the three models, respectively. The
sample size for all datasets is 300.
The outcome values y for the regression and survival models are generated under
different mechanisms. For the regression model, we add a Gaussian noise to the F (x, z)
values to generate y. The variance of the Gaussian noise is set to one-fifth of the F (x, z)
values’ variance.
For simulation of survival outcomes, we assume a Weibull baseline hazard h0(t) =
κρtρ−1, and cumulative hazard function H0(t) = κtρ, where κ and ρ are the scale and
shape parameters, respectively. Suppose that the score F (x, z) is calculated for one
sample. A corresponding survival time can be generated from
t =
(
− log(U)
κ exp[F (x, z)]
) 1
ρ
,
where U is randomly drawn from Uniform(0, 1) distribution.33 The values of κ and ρ are
chosen such that the median survival time is 20 months, which is on the same scale as
the median survival times of many cancer types. We then randomly draw 20% of the
samples for censoring, and the censoring times are drawn from a uniform distribution
between zero and the generated survival times.
When evaluating prediction performance, we use mean square error (MSE) for re-
gression, and C-index for the survival model.34 C-index is commonly used in assessing
survival prediction accuracy. In general, C-index looks at all possible pairs of samples,
and calculates the ratio of the pairs where the predicted risk scores are concordant with
the observed survival times. If the predicted risk score is not informative, C-index would
be close to 0.5. On the contrary, if the model perfectly predicts risk score, C-index would
be 1. More details regarding the calculation of C-index can be found in Appendix C
in the Supplementary Materials. For each dataset, we perform ten runs of the PKB
algorithm. In each run, we use two-thirds of the samples as training data, and assess
prediction performance on the remaining samples.
3.1 Simulation results for the regression model
We compared the performance of the PKB regression model to several existing methods,
including LASSO,23 Ridge Regression,24 and ElasticNet,25 which are linear models, and
RandomForest,35 Gradient Boosting Regression (GBR),14 and Support Vector Regres-
sion (SVR),36 which are nonlinear models. We extensively tuned the parameters for all
methods, and the configuration details are provided in Appendix D in the Supple-
mentary Materials. Table 1 compares the average MSE on test data over 10 runs.
Standard deviations of the MSEs can be found in Appendix H in the Supplementary
Materials.
In all simulation scenarios, the two PKB algorithms, PKB-L1 (with L1 model com-
plexity penalty) and PKB-L2 (with L2 model complexity penalty), yielded significantly
better prediction accuracy than competing methods. Among the competing methods, the
sparse linear models had better accuracy in Models 1 and 2, where only three pathways
are informative. Since there are eight pathways relevant to the outcome in Model 3, the
nonlinear genomic signal becomes stronger, thus the nonlinear methods produced equal or
better accuracy than the linear methods. We also assessed the ability of PKB to properly
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weigh the informative pathways. For each pathway, we calculated its weights in the final
score function over the ten runs. The distributions of the weights are presented in Figure
1. In all simulation scenarios, the PKB algorithm gave relevant pathways significantly
higher weights than the other pathways. Note that PKB shrank the weights of some, but
not all the noise pathways to zero. This is expected, because as the boosting procedure
continues, the predictive effect from true informative pathways becomes weaker, and the
noise pathways may occasionally result in the smallest loss and subsequently be selected
in certain iterations.
3.2 Simulation results for the survival model
In the survival analysis simulations, we compared our method with Glmnet,26 Random-
SurvivalForest,27 and CoxBoost.28 Glmnet is an extension of the Cox regression model
with penalties, and is commonly used in the analysis of survival data with high dimen-
sional predictors. RandomSurvivalForest and CoxBoost are also extensions of Random
Forest and CoxBoost, respectively, to perform survival analysis. Predictive performance
was evaluated using C-index. The average C-index for each method over the ten runs is
presented in Table 2, and the standard deviations are available in Appendix H in the
Supplementary Materials.
Both PKB methods significantly outperformed the competing methods in all simu-
lation scenarios. We also examined the pathway weights, similar as in the regression
simulations. The results suggest that the PKB survival model could effectively identify
informative pathways and weigh them properly in the score function. The weights distri-
bution figure has a similar pattern to Figure 1 from the regression simulations and we
leave it in Appendix F in the Supplementary Materials.
4 Applications
In order to examine the performance of our proposed model on real datasets, we applied
PKB, along with all the competing methods, to two cancer-related databases: CCLE29
for regression analysis, and TCGA for survival analysis.
We followed the same procedure as that in simulation studies to assess the perfor-
mances of the methods. In the applications of PKB, pathway annotation databases,
including the Kyoto Encyclopedia of Genes and Genomes (KEGG),37 Biocarta,38 and,
Gene Ontology Biological Process (GO-BP)39,40, were used as sources of pathway infor-
mation. Details about the choices of model parameters can be found in Appendix D in
the Supplementary Materials.
4.1 The CCLE drug response prediction
The CCLE is a rich database containing cancer cell line responses to anti-cancer com-
pounds, and involves cell lines from over 20 cancer types and 24 anticancer compounds
with various targets. A compilation of RNA-seq gene expression data is available for
about 1000 cell lines, which enables the analysis of the association between genes and
drug responses.
Drug response is measured by the IC50 value in the CCLE database, which is defined
as the concentration needed for the compound to kill 50% of the tumor cells in the cell
culture.29 In our prediction implementation, the log-transformed IC50 value was used as
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the outcome variable for regression. For clinical predictors, we considered cancer types
and the gender of the cell line provider. We applied our method to predict responses
for six compounds (named after their corresponding targets) that have sufficient sample
sizes: EGFR, HDAC, MEK, RAF, TOP, and TUBB1.
Table 3 demonstrates the cross-validated prediction MSEs from PKB and all com-
peting methods, with the top two methods marked in bold. In five out of the six datasets,
at least one of the PKB methods appeared in the top two methods. In the MEK dataset,
both PKB-L1 and PKB-L2 were ranked as the top two methods, and there was substan-
tial difference in MSE comparing our methods with the competing methods (Appendix
H in the Supplementary Materials). Among pathways that have been identified as
important for the drug response, the KEGG Asthma pathway is informative for drug
responses to MEK inhibitors and RAF inhibitors.
4.2 The TCGA cancer patient survival prediction
In order to assess the predictive performance of PKB on real survival data, we applied the
PKB survival model to seven cancer study datasets, including (by primary tumor sites):
brain, head/neck, skin, lung, kidney, stomach, and bladder. The datasets were selected
using criteria such as large sample size with gene expression data and low censoring ratio.
The TCGA datasets include more complete clinical information compared to the cell line
datasets in CCLE. The clinical features we used generally included patient gender, age,
tumor subtype, site/laterality, and stage, which were available in almost all datasets and
had low missing rates.
The cross-validated prediction C-indices from all methods are presented in Table
4. The PKB methods were the top two methods for accuracy in five out of the seven
datasets, and there was substantial difference in C-index between PKB methods and
the competing methods (Appendix H in the Supplementary Materials). In the
remaining two cases, PKB also yielded performances (C-index difference < 0.01, not
significant) comparable to the top two methods. In the brain and kidney datasets, PKB
was most successful, which outperformed the third best method by 0.26 and 0.15 in terms
of C-index, respectively. For these two cancer patient survival prediction results, we also
backtracked the biological pathways, which are closely related to the outcome. For the
KEGG pathway, the neuroactive ligand receptor interaction turned out to be the most
significant for brain tumor patients’ survival, and for the GO pathway, homophilic cell
adhesion via plasma membrane seemed to be the most important pathway according to
the boosting procedure.
We further performed pathway enrichment analysis, and examined the p-values of the
pathways considered significant by PKB. (If a pathway took positive weights in at least
four out of ten runs of PKB, it was considered significant.) The enrichment analysis was
conducted on each dataset following the procedure in Appendix E in the Supplemen-
tary Materials. The enrichment analysis results for the brain, kidney, and lung cancer
datasets are presented in Figure 2. Results for other datasets are available in Appendix
E in the Supplementary Materials. We observe different enrichment patterns from
different datasets. In the lung dataset (bottom panel of Figure 2), the PKB significant
pathways are highly concentrated to the left, meaning that they are also considered sig-
nificant in the enrichment analysis. In the brain and kidney cancer, the PKB pathways
are more spread out: some of them appear at the top, but many others are not considered
significant by the enrichment analysis. This is not surprising, because enrichment anal-
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ysis looks at marginal associations between pathways and outcomes, while PKB models
additive effects. It is possible for pathways without strong marginal signals to be picked
out by PKB in the presence of other pathways in the model.
4.3 Comparison with models using only clinical features
The PKB score function contains a linear model of clinical features and a nonlinear model
of genomic features. It is natural to ask how much improvement the genomic part brings
to the prediction accuracy, compared to the clinical part. Considering that genomic data
is much more expensive to acquire compared to clinical data, it makes sense to acquire
genomic data only when the prediction accuracy can indeed be improved. We compared
the performances of the following three methods in both the CCLE and TCGA datasets:
the PKB methods which utilize clinical, genomic, and pathway information; linear models
with both clinical and genomic features; and linear models with only clinical features.
The results are presented in Figure 3.
The upper panel of Figure 3 shows the MSEs of the three methods on CCLE drug
response datasets. The “LM” method represents the best results from LASSO, Ridge
Regression, and ElasticNet. In four datasets (EGFR, HDAC, MEK, and TOP1), using
genomic information significantly improved the prediction MSE. In the MEK dataset,
the MSE difference between the linear models with and without genomic features is not
significant. However, using PKB can improve the accuracy significantly.
Comparison of the three models in the TCGA datasets is presented in the lower panel
of Figure 3. Glmnet was used to fit the linear models. Only in the skin cancer dataset,
using genomic information failed to offer predictive signals in addition to the clinical
features. In the six other datasets, PKB achieved significantly higher C-index than the
clinical-only Glmnet. However, when the genomic features were modeled using Glmnet,
the gain in C-index became moderate, and even failed to outperform the clinical-only
version on the stomach and bladder cancer datasets. The results indicate that PKB is
able to capture genomic signals more efficiently than Glmnet.
5 Discussion
In this article, we have extended the PKB framework proposed by Zeng et al.21 to perform
regression and survival analysis and incorporate clinical features as predictors by adding
a linear part to the base learner spaces. We have applied PKB to the CCLE datasets
to predict cancer drug responses on cell lines, and to the TCGA datasets to predict
cancer patients’ survival. In both applications, PKB achieved equal or superior prediction
accuracy than competing methods in most datasets. Especially in several TCGA datasets,
PKB had significantly improved the prediction accuracy. We have further compared
PKB with linear models that only use clinical predictors. These results indicate that
PKB can effectively capture genomic predictive signals in addition to clinical signals, and
significantly improve prediction performance.
In the PKB regression model, the final score F (x, z) function is an estimate of the
regression function, which can be used directly to predict the outcome variable. However,
in the survival model, F (x, z) is not an estimate of the patient’s survival time, but rather
an estimate to the risk score in the hazard function (Equation (1)). Since the baseline
hazard h0(t) is still unknown, we cannot provide direct estimates of patients’ survival
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times. Nonetheless, after an estimate for F (x, z) is acquired, it is easy to nonparametri-
cally estimate the baseline hazard function, and subsequently estimate the survival times.
We have also assumed that the clinical effects and pathway effects are additive, and
therefore no interactions between clinical features and pathways are modeled. In the
presence of categorical clinical features, informative pathways are supposed to be infor-
mative in all categories. This assumption, however, may be violated in real datasets. For
example, each CCLE dataset is a mixture of cell lines from several cancer types. Even
if a pathway is significant in one or two cancer types, it might not be predictive for all
cancer types.3 This may be why PKB has not made significant improvement in certain
CCLE prediction tasks. We have also tried to fit PKB for each cancer type separately,
but the small sample sizes made it difficult to identify true pathway signals.
In the calculation of kernel functions, all the genes in the same pathways have been
treated equally. It is possible that, by giving larger weights to important genes, the PKB
models can achieve better prediction accuracy. Suppose gene i takes weight wi > 0. We
can modify the calculation of the kernel functions to focus more on the highly weighted
genes and we propose the following modifications to the radial basis kernel and polynomial
kernel functions, respectively:
Krbf(u,v) = exp
[
−
∑
j wj(uj − vj)2∑
j wj
]
, Kpoly(u,v) =
(
1 +
∑
j wjujvj∑
j wj
)d
.
We have explored this idea using gene weights calculated from GeneMANIA,41 where
we can acquire physical interaction network between genes. The edges between genes
are annotated with interaction strength, and the total degrees of the genes are used as
the weights. We have utilized the above weighted kernel function to fit PKB models.
However, we did not observe significant difference in prediction performance compared
to the unweighted version. Detailed results are available in Appendix G in the Sup-
plementary Materials. We leave gene weights as an optional parameter when using
PKB, so that users are able to explore different ways to calculate weights for improved
prediction accuracy.
The current PKB algorithm can also be improved for better computational efficiency.
The 3-fold cross-validation step is the most time and space-consuming part of the model,
since it involves running three boosting processes at the same time. It is possible to adopt
the notion of out-of-bag (OOB) samples from RandomForest and GBR to calculate testing
loss in just one boosting process. In each iteration, instead of using all the samples, we
draw a bootstrap sample to train the increment function. The samples not selected in
the training set are treated as OOB samples, on which testing loss can be computed. It
has been reported that OOB often underestimates the optimal number of iterations,42
but brings the advantage of efficient model training, especially when the dataset is large.
A Python software implementing the PKB algorithms is available from Github repos-
itory: https://github.com/zengliX/PKB2. The data that support the findings of this
study are available from the corresponding author upon reasonable request.
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Figure 1: Boxplots for pathway weights in the regression simulations. Each box represents
the weights distribution for one pathway over ten PKB runs.
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Figure 2: Enrichment analysis on brain, kidney, and lung cancer datasets. X-axis repre-
sents pathways sorted by their p-values in the enrichment analysis. The blue dashed line
corresponds to p-value 0.05. The pathways marked with red bars and stars are pathways
with significant weights in PKB.
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Figure 3: Prediction performances from models with and without genomic features. The
figure presents the prediction accuracy from three types of models on each dataset. The
models include: PKB, linear model, and linear model with only clinical features as pre-
dictors. LM in the upper panel represents linear regression model, which reports the best
results from LASSO, Ridge Regression, and ElasticNet. The methods with label “clinical
only” are trained without genomic features. The PKB boxes represent the best results
from PKB-L1 and PKB-L2.
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Method
Model 1 Model 2 Model 3
M = 20 M = 50 M = 20 M = 50 M = 20 M = 50
PKB-L1 17.11 22.82 32.92 33.94 7.22 8.37
PKB-L2 16.84 22.41 31.25 33.65 5.4 5.77
LASSO 34.85 40.58 49.74 50.94 21.15 22.88
Ridge 50.71 53.1 57.32 60.52 23.25 25.99
ElasticNet 34.87 42.21 49.27 50.93 21.25 23.51
RandomForest 46.88 50.94 55.34 57.34 21.09 22.67
GBR 48.54 51.75 50.9 52.82 21.46 23.7
SVR 50.02 53.58 56.12 59.58 19.06 24.31
Table 1: Cross-validated MSE of all methods on simulated regression datasets. M rep-
resents the number of simulated pathways. For each dataset, MSE values from the top
two methods are in boldface.
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Method
Model 1 Model 2 Model 3
M = 20 M = 50 M = 20 M = 50 M = 20 M = 50
PKB-L1 0.9 0.86 0.77 0.77 0.88 0.87
PKB-L2 0.9 0.88 0.72 0.76 0.9 0.89
Glmnet 0.78 0.79 0.69 0.71 0.65 0.66
RandomSurvivalForest 0.67 0.67 0.65 0.67 0.63 0.64
CoxBoost 0.78 0.78 0.7 0.7 0.66 0.66
Table 2: Cross-validated C-indices of all methods on simulated survival datasets. M
represents the number of simulated pathways. For each dataset, C-indices from the top
two methods are highlighted in boldface.
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Method EGFR HDAC MEK RAF TOP1 TUBB1
PKB-L1 0.88 0.54 2.92 1.37 0.98 1.12
PKB-L2 0.88 0.54 2.9 1.35 1.01 1.12
LASSO 0.87 0.62 3.63 1.47 1.14 1.18
Ridge 0.84 0.52 3.28 1.39 1.01 1.19
ElasticNet 0.89 0.59 3.37 1.44 1.14 1.17
RandomForest 0.88 0.56 3.17 1.37 0.99 1.12
GBR 0.91 0.54 3.3 1.43 1.0 1.14
SVR 0.88 0.55 3.17 1.38 0.99 1.11
Table 3: Cross-validated MSEs from all methods on CCLE drug response data. For each
dataset, the two methods with the smallest MSEs are marked in boldface.
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Method Brain Head/Neck Skin Lung Kidney Stomach Bladder
PKB-L1 0.86 0.62 0.66 0.59 0.78 0.66 0.67
PKB-L2 0.85 0.61 0.64 0.57 0.77 0.65 0.67
Glmnet 0.59 0.62 0.67 0.54 0.62 0.56 0.6
RandomSurvivalForest 0.58 0.54 0.63 0.54 0.58 0.54 0.52
CoxBoost 0.59 0.62 0.67 0.53 0.61 0.53 0.6
Table 4: Cross-validated C-index from all methods on CCLE drug response data. For
each dataset, the two methods with the highest C-index are marked in boldface.
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